RxDoctor Payments DataLook up a doctor →

Paul Bradley, MD

Internal Medicine · Savannah, GANPI 1952349813

Payments from drug & device makers

$76,382,506in general payments, 2019–2025

Across 9,237 payments — averaging $8269.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$58.9M
  • Pfizer$9.1M
  • Seqirus USA Inc$1.5M
  • GSK$981K
  • Emergent Biosolutions Inc.$937K
  • Bavarian Nordic A/s$807K
  • plus $4.1M from 54 others
$1,108in research payments, 2019–2025

Across 5 payments — averaging $221.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novavax Inc$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.4,733$58,937,953
Pfizer559$9,099,832
Seqirus USA Inc585$1,540,474
GSK181$980,823
Emergent Biosolutions Inc.998$936,942
Bavarian Nordic A/s103$806,540
Sanofi Pasteur Inc.34$748,609
Johnson & Johnson76$639,131
Vertex3$638,434
Alnylam Pharmaceuticals Inc.763$528,437
Biontech SE46$227,132
Janssen Research & Development, LLC8$219,543
Novartis58$143,198
CSL Behring9$140,835
AstraZeneca(2 entities)36$138,460
Novavax Inc12$98,327
Amgen(2 entities)80$89,024
Lucid Diagnostics Inc.4$76,193
Boehringer Ingelheim International GmbH159$71,219
AbbVie(2 entities)207$64,855
Bayer32$49,085
Boehringer Ingelheim20$44,559
Novo Nordisk AS14$33,459
Boehringer Ingelheim Pharma GmbH & Co.kg11$23,840
Astrazeneca UK Limited1$21,800
Tolmar, Inc.4$17,981
Merck39$16,068
Regeneron4$14,737
Valneva Austria GmbH1$7,500
Takeda Pharmaceuticals U.S.A., Inc.6$5,150
Teva Pharmaceuticals USA, Inc.21$4,555
Kowa Research Institute, Inc.2$3,549
Sanofi-aventis U.S. LLC10$2,715
Eli Lilly2$2,423
Boehringer Ingelheim Limited2$2,096
Novo Nordisk116$1,449
Otsuka America Pharmaceutical, Inc.21$450
Astellas Pharma US Inc25$439
Lilly USA, LLC21$419
Lundbeck LLC14$308
Esperion Therapeutics, Inc.20$293
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$270
Dexcom, Inc.11$232
Amarin Pharma, Inc.10$195
Radius Health, Inc.8$188
Idorsia Pharmaceuticals US Inc9$183
Antares Pharma, Inc.8$171
Eisai Inc.9$135
Bausch Health US, LLC4$120
Currax Pharmaceuticals LLC8$113
Pacira Therapeutics, Inc.1$106
Biohaven Pharmaceuticals, Inc.5$101
Sunovion Pharmaceuticals Inc.8$101
E.r. Squibb & Sons, L.L.C.6$89
Axsome Therapeutics, Inc.3$81
Ironwood Pharmaceuticals, Inc4$81
Boston Scientific4$81
Mannkind Corporation2$76
Biohaven Pharmaceutical Holding Company Ltd.3$72
Xeris Pharmaceuticals, Inc.3$70

How this compares

$76,382,506 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia →

Medicare billing

Part B allowed, 2024
$475,968
Medicare patients
630
Services billed
9,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Savannah

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →